Angio8 Secures Tens of Millions in Series A Funding to Accelerate Development of Vascular Interventional Surgical Robots

On May 8, Shenzhen Tongyong Technology Co., Ltd. (hereinafter referred to as “Tongyong Tech”) announced the successful completion of its Series A financing round, securing tens of millions of RMB in investment. The round was led by Oriental Fortune Capital, with participation from prominent investment firms including HWealth Capital. These investors bring extensive strategic expertise and industry resources in the healthcare sector, providing strong support for Tongyong Tech’s future development.

Tongyong Technology was established in December 2021, with its headquarters located in Nanshan District, Shenzhen. The company is dedicated to addressing the most advanced development needs of vascular interventional surgery by conducting in-depth independent research and development of next-generation surgical robots that are at the forefront of global technology, as well as pioneering research in related information fields. It has created the world’s first innovative platform for vascular interventional surgical robots, providing intelligent surgical solutions. The company’s core team comprises seasoned professionals from the medical device industry and renowned international experts in surgical robot technology. Leveraging its existing core technological advantages and the geographic benefits of its R&D center in Boston, USA, Tongyong Technology is not only deepening its expertise in vascular interventional surgery but also developing artificial intelligence systems that integrate virtual and physical elements, thereby expanding the application of surgical robots to other scenarios.

Starting with cardiovascular care, the company will develop a comprehensive AI system that integrates virtual and physical components to recreate and simulate realistic surgical environments and scenarios. This will not only enable physicians to conduct effective preoperative planning and practice but also generate vast amounts of real-world surgical data, thereby enhancing the AI system’s ability to assist doctors in actual surgical procedures.

The founding team of Tongyong Technology stated:“We are deeply grateful for the trust and support from our investors. This funding will be used to accelerate our product development and advance it into the clinical stage. We remain committed to delivering superior surgical solutions, enabling more patients to benefit from internationally leading medical services. Through our efforts, we aim to expand the growth potential and market outlook of the entire surgical robotics sector.”

Wang Peijun, Partner at Shenzhen Oriental Fortune Capital, stated:Cardiovascular and cerebrovascular diseases pose a severe threat to human health. Globally, up to 15 million people die from these conditions annually, ranking them as the leading cause of death. With the acceleration of population aging and urbanization, the number of patients with cardiovascular and cerebrovascular diseases is expected to continue rising. Currently, traditional interventional procedures and consumables have become the mainstream treatment options, but they are associated with numerous adverse reactions. Tongyong Medical has developed a portfolio of products, including intravascular ablation technologies and vascular surgical robots, covering multiple clinical scenarios in cardiovascular and cerebrovascular care. Its product series has demonstrated advantages in practice, such as minimal procedural trauma, durable efficacy, and fewer long-term adverse events, effectively addressing significant unmet clinical needs. The company’s products and services will continuously expand to cover a broader range of scenarios, including coronary and peripheral interventions. Tongyong Medical remains committed to optimizing the learning curve for surgical techniques, improving procedural efficiency, enhancing treatment outcomes, and extending its reach to primary healthcare institutions. We wish the company continued success in leveraging technological innovation to benefit more patients.

Dr. Zhou Ping, Executive Director of HWealth Capital, stated:Driven by the substantial cumulative implant volume and annual procedure volume of coronary stents both domestically and internationally, coronary plaque ablation and vascular intervention robotics have emerged as two new super-segments within the high-end medical device sector. Furthermore, leveraging the platform-based nature of Tongluo Technology’s proprietary technology and the vast patient population, the markets for peripheral vascular stenosis ablation and vascular intervention robotics represent two additional potential super-segments. Impressively, Tongluo Technology’s founding team comprises top-tier international talent and boasts a proven track record in the development and commercialization of active implantable devices and surgical robots. Within just one year of its establishment, the company completed prototype development for two core products, preliminarily validated their efficacy, and demonstrated that its technological approach effectively addresses global technical challenges associated with these two product categories. HWealth Capital is optimistic about the founding team’s deep technical expertise, innovative capabilities, and efficient execution, and is committed to supporting Tongluo Technology’s growth into an international platform company in the fields of energy platforms and medical robotics.

SME Development Fund (Chengdu) Jiaozi Venture Capital Partnership (Limited Partnership) (“Chengdu Fund”) is a national-level fund approved by the Executive Meeting of the State Council. It was spearheaded by five ministries and commissions—the Ministry of Finance, the Ministry of Industry and Information Technology, the Ministry of Science and Technology, the National Development and Reform Commission, and the State Administration for Industry and Commerce—along with China SME Development Fund Co., Ltd., with Shenzhen Oriental Fortune Capital Co., Ltd. serving as the fund manager. The Chengdu Fund is the only national SME Development Fund established in the three southwestern provinces of China. Aimed at aligning with national policy objectives to promote innovation and development among small and medium-sized enterprises (SMEs), the fund leverages market-oriented mechanisms to expand equity investment in SMEs. It prioritizes supporting high-growth SMEs in their seed and early start-up stages, thereby playing an active role in fostering new business formats, new models, new growth drivers, and new momentum. With a total size of RMB 5 billion, the Chengdu Fund focuses on investing in strategic emerging industries designated by the state, including information technology, healthcare, semiconductors, new materials, and new energy.

HWealth Capital was jointly established by high-performing senior healthcare investors, shareholders of major listed pharmaceutical companies, and industry leaders who are global pioneers and China’s frontrunners in specialized medical sectors. The firm is committed to building an industrialized healthcare investment fund deeply driven by “industry research, scientific research, and operational expertise.” Its core team members hail from leading domestic and international healthcare institutions and research institutes. HWealth Capital has previously invested in and incubated numerous technological and market leaders in specialized segments both in China and abroad, including: PINS Medical, Hehu Technology, Yanwei Technology, U-Jia Health, Tonglu Technology, Wushuang Medical, Ascentage Pharma (6855.HK), Shenzhen Kangtai Biological Products (300601.SZ), Meinian Onehealth Healthcare Holdings (002044.SZ), Kangzhong Medical (688607.SH), Nikkiso Co., Ltd. (6376.JP), Houkai Medical, and Hisky Medical Technology, among others. HWealth Capital focuses on the diagnosis and treatment of major diseases in neurology, oncology, autoimmune disorders, and other therapeutic areas, with a particular emphasis on investing in best-in-class or original diagnostic and therapeutic products that address substantial market opportunities and are supported by rigorous mechanistic and clinical data.